Kodu>Kliinilised uuringud>Kliinilised uuringud>XIRIUS

How to use the speech recognition tool?

NCT03116113

XIRIUS

A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR).

Type: Interventional



Status of the trial: Completed

Orphan Drug Recognition: No

Inclusion

  • Opening Date: 2017-08-01
  • Closing Date: 2018-01-31

Criteria

More information

Children: Yes

Adults: Yes

Funder Type: industry

HCP: Other investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Retinal Rare Eye Diseases (WG1)

Subscribe to our mailing list

* indicates required

This ERN is supported by: